Your browser doesn't support javascript.
loading
COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.
Bou-Antoun, Sabine; Rokadiya, Sakib; Ashiru-Oredope, Diane; Demirjian, Alicia; Sherwood, Emma; Ellaby, Nicholas; Gerver, Sarah; Grossi, Carlota; Harman, Katie; Hartman, Hassan; Lochen, Alessandra; Ragonnet-Cronin, Manon; Squire, Hanna; Sutton, J Mark; Thelwall, Simon; Tree, Julia; Bahar, Mohammad W; Stuart, David I; Brown, Colin S; Chand, Meera; Hopkins, Susan.
Afiliação
  • Bou-Antoun S; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
  • Rokadiya S; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
  • Ashiru-Oredope D; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
  • Demirjian A; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
  • Sherwood E; Department of Paediatric Infectious Diseases & Immunology, Evelina London Children's Hospital, London, UK.
  • Ellaby N; Faculty of Life Sciences & Medicine, King's College London, London, UK.
  • Gerver S; Clinical and Emerging Infections (CEI), United Kingdom Health Security Agency (UKHSA), London, UK.
  • Grossi C; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
  • Harman K; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
  • Hartman H; COVID-19 Rapid Evidence Service Public Health Advice, Guidance and Expertise (PHAGE), UK Health Security Agency, London NW9 5EQ, UK.
  • Lochen A; COVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency, London NW9 5EQ, UK.
  • Ragonnet-Cronin M; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
  • Squire H; Tuberculosis (TB), Acute Respiratory, Zoonoses, Emerging and Travel infections Division, UK Health Security Agency, London NW9 5EQ, UK.
  • Sutton JM; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
  • Thelwall S; MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.
  • Tree J; Department of Ecology and Evolution, University of Chicago, Chicago, IL, USA.
  • Bahar MW; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
  • Stuart DI; Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
  • Brown CS; Institute of Pharmaceutical Sciences, King's College London, London, UK.
  • Chand M; COVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency, London NW9 5EQ, UK.
  • Hopkins S; Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
J Antimicrob Chemother ; 78(Suppl 2): ii37-ii42, 2023 11 23.
Article em En | MEDLINE | ID: mdl-37995354
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido